Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ILK | Q13418 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11162902 | 0.91 | RAB9A (0.47) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18554384 | 0.84 | DYRK1A (0.53) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2098849 | 0.81 | RAB9A (0.56) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2217147 | 0.79 | HTT (0.66) | DYRK1AAPPMAPTHTTGAA | |
| SCHEMBL4137369 | 0.78 | PPARA (0.57) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11691297 | 0.76 | SMN1; SMN2 (0.61) | RAB9ANPC1APPMAPTHTT | |
| SCHEMBL141868 | 0.76 | RAB9A (0.51) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1853837 | 0.76 | RAB9A (0.51) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12844692 | 0.76 | GFER (0.61) | RAB9ANPC1DYRK1AAPPMAPT | |
| SCHEMBL9883331 | 0.76 | RAB9A (0.51) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4298097-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230391764-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | disclosed |
| CN-116897155-A | Benzothiazolyl bicyclo [1.1.1] pentane derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022180003-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-09-01 | — | — | WO | disclosed |
| EP-2739612-B1 | COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE UPTAKE AND INSULIN SECRETION | YISSUM RES DEV CO (IL) | 2017-06-21 | — | — | EP | disclosed |
| US-9409904-B2 | Compounds and compositions for use in augmentation of glucose | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-08-09 | — | — | US | disclosed |
| US-9409904-B2 | Compounds and compositions for use in augmentation of glucose | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-08-09 | — | — | US | disclosed |
| US-20150025094-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-01-22 | — | — | US | disclosed |
| US-20150025094-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-01-22 | — | — | US | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-4474965-A | PLANT GROWTH AGENTS | MONSANTO COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0007772-B1 | N-SUBSTITUTED BENZOTHIAZOLINES AND BENZOXAZOLINES AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULANTS | MONSANTO COMPANY (US) | 1983-09-07 | — | — | EP | disclosed |
| US-4371388-A | 3-Substituted aminoalkyl-2-benzothiazolinones as plant growth regulants | MONSANTO COMPANY (US) | 1983-02-01 | — | — | US | disclosed |
| US-4336060-A | N-Substituted benzothiazolines and benzoxazolines and their use as herbicides and plant growth regulants | MONSANTO COMPANY (US) | 1982-06-22 | — | — | US | disclosed |
| US-4228292-A | N-Substituted benzothiazolines and benzoxazolines and their use as herbicides and plant growth regulants | MONSANTO COMPANY (US) | 1980-10-14 | — | — | US | disclosed |
| EP-0007772-A1 | N-substituted benzothiazolines and benzoxazolines and their use as herbicides and plant growth regulants | MONSANTO COMPANY (US) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025094-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE | SLC5A2, SLC2A2, SLC2A1 | RAB9A 4032/4885NPC1 846/4885CYP1A2 152/4885 |
| US-20230391764-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, SLC10A1, BCL2A1 | RAB9A 1769/4885NPC1 195/4885CYP1A2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.